Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in a $4.9 Billion Deal
In a multibillion-dollar deal within the biotechnology sector, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leader...
NASDAQ: VRTX
FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia
Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...
Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...